Sterile compounding for home therapy

September 4, 2025

Introduction to Sterile Compounding for Home Therapy

Sterile compounding in home therapy is an essential aspect of modern healthcare, allowing patients to receive necessary medications tailored to their needs in a safe environment outside the hospital. This practice involves the preparation of compounded sterile preparations (CSPs) that maintain the highest standards of sterility, safety, and accuracy. In this article, we delve into the practices, regulations, and standards that govern sterile compounding, offering insights into how they ensure effective patient care and safety in home environments.

Understanding USP 797 Guidelines

What are the USP 797 guidelines for sterile compounding?

The USP 797 guidelines establish vital standards for the preparation of compounded sterile preparations (CSPs) in pharmacy settings. These guidelines aim to ensure patient safety and minimize possible risks associated with sterile compounding practices. Under these regulations, CSPs are organized into three risk categories: low, medium, and high. Each category accounts for different factors, including the compounding environment and sterility testing requirements, while also assigning specific Beyond Use Dates (BUDs) for each type.

Updates effective from November 1, 2023

Beginning November 1, 2023, an updated version of USP 797 will come into effect. This revision includes some key modifications, such as a refined definition for immediate use compounding, which now allows for a maximum BUD of 4 hours and limits the preparation to only three different sterile products. The updated guidelines enhance cleaning and disinfection protocols, mandating the use of sterile cleaning solutions and sporicidal agents. Additionally, personnel handling the compounding process must complete annual training to maintain competency, with a strong focus on contamination prevention and quality assurance of medications.

Categorization of CSPs

CSPs are classified into three categories based on contamination risk and preparation complexity:

Risk Level Description Specific Considerations
Low Simple preparations in controlled environments Typically involve one or two sterile products in a cleanroom setting, requiring basic sterility protocols.
Medium More complex preparations Involves multiple ingredients or longer preparation times; requires more rigorous testing.
High High-risk preparations Often includes hazardous drugs or preparations that must meet stringent sterility standards to prevent patient harm.

The classification helps determine the appropriate protocols to ensure the safety and quality of CSPs prepared for home infusion therapy.

The Role of Home Infusion Therapy

Can infusion therapy be conducted at home?

Yes, infusion therapy can be conducted at home through a process known as home infusion therapy. This method involves the intravenous or subcutaneous delivery of medications or biologicals. Essential components include:

  • The drug : Prescribed and tailored to meet patient-specific needs.
  • Equipment : Such as infusion pumps, requiring careful setup and monitoring.
  • Supplies : Including sterile tubing and catheters for safe delivery.

Additionally, professional nursing services are typically involved to ensure proper administration and patient care at home.
Under the 21st Century Cures Act, Medicare introduced a benefit for home infusion therapy effective from January 1, 2021, which covers professional services related to this therapy.

What professional services are involved in home therapy?

The provision of home infusion therapy engages multiple professional services:

  • Pharmacists : They prepare compounded sterile preparations (CSPs) and ensure compliance with rigorous standards, specifically USP <797>, to safeguard patient health.
  • Infusion Nurses : They educate patients on the administration of therapies and monitor ongoing treatment, playing a crucial role in managing patient care.
  • Pharmacy Technicians : They assist in the compounding processes, ensuring that the medications are prepared under sterile conditions, critical for patient safety.

How is care coordinated in home infusion therapy?

Coordination among care providers is vital for the success of home infusion therapy. Key aspects include:

  • Thorough patient assessments : Before initiating therapy, pharmacists and nurses evaluate the patient's suitability for home care.
  • Communication : Clear documentation and frequent communication between pharmacists, nurses, and healthcare providers ensure a seamless treatment journey.
  • Ongoing monitoring : Regular follow-ups are crucial to adjust therapies as needed, ensuring the highest quality of care throughout the patient's treatment process.

Home infusion therapy not only offers flexibility for patients but also empowers them to receive essential medications safely within the comfort of their homes.

Common Medications for Home Infusion

Which drugs are commonly infused at home?

Home infusion therapy involves a diverse range of medications tailored to meet individual patient needs. Common medications infused at home include:

  • Antimicrobial Therapies :

    • Acyclovir : Used to treat viral infections.
    • Meropenem : A broad-spectrum antibiotic for severe infections.
    • Amikacin : An aminoglycoside antibiotic effective against resistant infections.
    • Vancomycin : Essential for combatting vancomycin-resistant pathogens.
  • Antiemetics :

    • Ondansetron : Helps manage nausea and vomiting, particularly for chemotherapy patients.
    • Granisetron : Another antiemetic effective in similar situations.
  • Cardiac Therapies :

    • Dobutamine : Used to treat heart failure and low cardiac output.
    • Furosemide : A diuretic for managing fluid retention and heart conditions.
  • Corticosteroids :

    • Dexamethasone : Reduces inflammation and treats various conditions.
    • Methylprednisolone : Another anti-inflammatory medication.

Additionally, home infusion patients may receive hydration solutions and total parenteral nutrition (TPN), ensuring they maintain nutritional needs while managing their daily routines comfortably at home. The flexibility of these therapies significantly contributes to improved quality of life for patients requiring ongoing treatment.

Maintaining a Sterile Compounding Environment

What are the requirements for sterile compounding environments?

Maintaining a sterile environment is critical in the preparation of compounded sterile preparations (CSPs). Key requirements include:

  • Air Quality Standards : Compounding areas must meet an ISO level of 5 or better. This is vital to ensure that the cleanliness and airborne particle levels are controlled effectively.
  • Airflow Management : Unidirectional airflow is essential, supported by HEPA filtration systems. Regular airflow studies are conducted to maintain the integrity of the air quality, which is crucial for preventing contamination.
  • Personal Protective Equipment (PPE) : All personnel involved in compounding must wear appropriate PPE to minimize any risk of contamination during the compounding process.
  • Labeling Standards : CSPs must be labeled clearly with a Beyond-Use-Date (BUD) to assure that the preparations are used within safe time frames, adhering to cGMP and USP <797> guidelines.

How is quality assurance achieved in sterile compounding?

Quality assurance in sterile compounding primarily involves several systematic practices:

  • Routine Environmental Monitoring : Regular checks for viable and nonviable particles, along with temperature and pressure monitoring, help to maintain sterile conditions.
  • Cleaning Protocols : Strict adherence to cleaning and disinfecting protocols is critical to prevent contamination of the compounding area.
  • Documentation and Compliance : Accurate documentation of all compounding processes and adherence to safety standards ensure that CSPs meet regulatory requirements.

Overall, these standards and practices bolster the safety and efficacy of CSPs used in home infusion therapy.

ASHP Guidelines for Sterile Compounding Practices

What are the ASHP guidelines on compounding sterile preparations?

The ASHP guidelines on compounding sterile preparations outline the critical responsibilities of pharmacy personnel—primarily pharmacists and pharmacy technicians—focused on ensuring the quality and safety of compounded sterile preparations (CSPs). Revised from the 2000 guidelines, they align with USP Chapter <797>, categorizing CSPs into three risk levels: low, medium, and high. Each category comes with specific aseptic technique and monitoring requirements to mitigate contamination risks.

In addition to categorization, the guidelines emphasize legal and regulatory compliance, highlighting the necessity of stringent cleaning procedures and environmental monitoring. Adhering to these standards is crucial for upholding cleanliness and sterility in compounding environments. ASHP also provides resources and training tailored to help pharmacies conform to updated standards, particularly the latest revisions effective as of November 1, 2023.

What roles do pharmacy personnel play in sterile compounding?

Pharmacy personnel, especially pharmacists and technicians, play a pivotal role in sterile compounding. They must be well-versed in aseptic techniques and the specific challenges of compounding in home care settings. Staff must undergo training that includes hand hygiene, cleaning and disinfection, and documentation of compounding processes.

Moreover, they are responsible for implementing protocols that effectively manage the complexities associated with longer storage times and multi-ingredient preparations, such as total parenteral nutrition (TPN). Through this rigorous training and adherence to ASHP guidelines, pharmacy personnel can significantly enhance patient safety and the efficacy of infusion therapies.

Understanding the 10% Rule in Sterile Compounding

What is the 10% rule for sterile compounding?

The 10% rule for sterile compounding is a critical guideline designed to ensure accurate dosing of injectable medications, especially in intravenous (IV) solutions. This rule states that if the volume of added medications exceeds 10% of the total volume indicated on the bulk solution container, an adjustment must be made by removing an equivalent amount of fluid from the IV bag.

This practice is vital for maintaining the correct drug concentrations within the solution. An overfill can lead to significant variations in the actual dosing, potentially resulting in patient safety risks and reduced efficacy of treatment. For instance, mismanagement of overfill has previously caused scenarios where patients received diluted chemotherapy solutions, impacting their treatment outcomes.

To mitigate such risks, healthcare organizations are strongly encouraged to standardize preparation methodologies, improve documentation protocols, and enhance labeling practices in sterile compounding environments.

Accurate dosing of medications

Adhering to the 10% rule helps pharmacists and technicians ensure that every compounded sterile preparation is both safe and effective. Accurate dosing is particularly important in sensitive patient populations, where precise medication administration can mean the difference between successful recovery and adverse effects. By implementing stringent controls and training for personnel in sterile compounding techniques, home infusion providers can safeguard against the pitfalls of improper dosing and maintain high standards of patient care.

Conclusion: The Future of Home Therapy Through Sterile Compounding

As the demand for home healthcare continues to grow, so does the need for sterile compounding services that can deliver safe, effective, and personalized care outside traditional medical settings. The evolving standards and guidelines ensure that medications are prepared with precision and care, safeguarding patient health and enhancing quality of life. By adhering to these stringent practices and continuously improving their processes, home infusion pharmacies can meet the diverse needs of their patients, providing critical treatments that help manage complex conditions from the comfort of one's home.

References

Low Albumin in Dialysis Patients
June 3, 2026
Low albumin is a key marker of malnutrition in dialysis patients. Learn what causes albumin decline, when IDPN is indicated, and how Pharmko supports renal nutrition across 22+ states.
Home Infusion Pump Types
June 2, 2026
Learn about the different types of infusion pumps used in home therapy, ambulatory, electronic, elastomeric, and CADD pumps, and how your pump is matched to your specific treatment.
Home Infusion for Rheumatoid Arthritis
May 30, 2026
Learn how home infusion therapy works for rheumatoid arthritis — including Remicade (infliximab) and other IV biologics, who qualifies for home treatment, and how Pharmko supports ongoing RA care.
Sterile Compounding Safety
May 26, 2026
When a patient or provider chooses a compounding pharmacy to prepare IV medications, they are trusting that the pharmacy operates under rigorous, independently enforced standards. In the United States, those standards are defined by two chapters of the United States Pharmacopeia: USP <797> for sterile compounding and USP <800> for hazardous drug handling. Pharmko operates in full compliance with both chapters. Understanding what these standards require, and what happens when they are not met, helps patients and providers make informed decisions about which pharmacy they trust with their care. What Is USP <797>? USP <797> (Pharmaceutical Compounding, Sterile Preparations) is the national standard that defines the minimum requirements for compounding sterile preparations safely. It covers: Cleanroom environment classification, ISO Class 5 at the point of compounding, ISO Class 7 for the surrounding buffer area, ISO Class 8 for the ante-room Personnel training, gowning, and aseptic technique requirements Sterilization and filtration methods by product type Beyond-use dating (BUD), how long a compounded sterile preparation remains safe to use Environmental and personnel monitoring schedules Quality assurance, documentation, and deviation management USP <797> applies to every pharmacy that prepares IV solutions, injections, eye drops, or other sterile preparations, whether they are a hospital pharmacy, ambulatory infusion center, or specialty pharmacy like Pharmko. The 2023 Revision: What Changed USP <797> was significantly revised in 2023 (effective November 2023). Key changes include: Stricter beyond-use date requirements, compounded sterile preparations must now meet more conservative dating limits unless sterility testing supports extended dating Enhanced environmental monitoring, more frequent air and surface sampling with defined action levels Clearer personnel qualification requirements, competency assessments are now required at defined intervals New category system, preparations are now categorized (Category 1 and Category 2) based on sterility assurance level and BUD Pharmacies that were compliant under the previous version of USP <797> must have updated their procedures and infrastructure to meet the 2023 revision. Pharmko updated our facilities, policies, and documentation systems in alignment with the revised chapter. What Is USP <800>? USP <800> (Pharmaceutical Compounding, Hazardous Drugs) establishes standards for the safe handling of hazardous drugs throughout the pharmacy, from receipt and storage to preparation, dispensing, and waste disposal. Hazardous drugs include certain chemotherapy agents, antiviral medications, hormones, and other drugs that pose risks of carcinogenicity, reproductive toxicity, or organ damage at low exposure levels. USP <800> requires: Negative-pressure ventilated containment primary engineering controls (C-PECs) for hazardous drug compounding Separate, dedicated hazardous drug storage areas Personal protective equipment (PPE) requirements for all staff handling hazardous drugs Closed-system drug transfer devices (CSTDs) for certain preparations Spill kits and exposure management protocols Why These Standards Matter for Patients The consequences of non-compliance are serious. High-profile compounding pharmacy failures, including a 2012 fungal meningitis outbreak linked to contaminated steroid injections that killed 64 patients and injured hundreds, demonstrated what happens when sterile compounding standards are not followed. For patients receiving home IV therapy, USP <797> compliance is not a credential to check once and forget, it reflects the ongoing daily practices of the pharmacy preparing their medications. Patients and providers should verify that any pharmacy preparing their IV solutions is accredited, state-licensed, and actively compliant with current USP standards. How Pharmko Meets These Standards Pharmko's sterile compounding facility is designed, staffed, and operated to meet USP <797> and USP <800> requirements. We are ACHC accredited, state-licensed in 22+ states, and subject to regulatory inspection. Every batch we compound is reviewed by a licensed pharmacist, and our environmental and personnel monitoring data is reviewed on a defined schedule. For a broader overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . For providers interested in our compounding capabilities, see our physician services page or contact our pharmacy team directly. → Contact Pharmko about sterile compounding: 1-877-540-2003
What Is Sterile Compounding and Why Does It Matter for IV Therapy?
May 19, 2026
When a patient needs a medication that is not commercially available in the right dose, formulation, or combination, a sterile compounding pharmacy creates it. Sterile compounding is the process of preparing customized, injectable or infusible medications, IV solutions, eye drops, inhalation solutions, in a controlled, contamination-free environment. Pharmko's sterile compounding services are at the core of what makes specialty pharmacy different from a retail pharmacy. Every IV medication we prepare is custom-compounded, validated, and released by a licensed pharmacist before it reaches a patient. What Makes Compounding 'Sterile'? The word 'sterile' refers to the absence of viable microorganisms, bacteria, fungi, endotoxins, in the final product. This is non-negotiable for any medication injected into or infused through the body. A contaminated IV solution can cause severe bloodstream infections, sepsis, or death. Achieving sterility requires: A controlled cleanroom environment (ISO Class 5 or better at the point of compounding) Positive or negative air pressure depending on the type of medication being prepared Gowning, gloving, and aseptic technique by trained pharmacy staff Validated sterilization methods (filtration, terminal sterilization) appropriate for each formulation Environmental and personnel monitoring to detect contamination risks before they reach patients How Sterile Compounding Differs from Retail Pharmacy A retail pharmacy dispenses commercially manufactured medications in their existing forms — tablets, capsules, pre-made liquids. A sterile compounding pharmacy like Pharmko creates medications that either do not exist commercially, are no longer commercially available, or must be customized for a specific patient. Examples of why sterile compounding is necessary: A patient needs a specific antibiotic concentration not available in commercial vials TPN must be formulated individually based on the patient's weight, labs, and nutritional requirements — no pre-made product covers every case A pediatric patient needs a lower concentration of an IV medication than any commercial product offers IV antibiotics must be prepared in specific volumes and concentrations for OPAT patients based on the prescribed regimen What Is USP <797>? USP <797> is the United States Pharmacopeia chapter that sets the standards for sterile compounding. It defines the environmental requirements, beyond-use dating, testing, personnel training, and quality systems that a pharmacy must maintain to legally compound sterile preparations. Compliance with USP <797> is required by state pharmacy boards and enforced through inspections. Not all compounding pharmacies meet these standards — patients and providers should verify that any pharmacy preparing IV medications is operating in full USP <797> compliance. For a detailed breakdown of what USP <797> and the newer USP <800> standard mean for patient safety, see our guide on sterile compounding safety standards . How Pharmko's Compounding Process Works Pharmko operates a state-of-the-art USP <797> compliant sterile compounding facility. Every product we prepare goes through: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained pharmacy technicians in an ISO Class 5 laminar airflow workbench or biological safety cabinet In-process and final product checks by a licensed pharmacist Sterility testing or filtration validation where required Cold-chain delivery to the patient or dialysis clinic within validated stability windows Why It Matters for Home Infusion Patients Every IV therapy delivered through Pharmko's home infusion services is compounded in our sterile facility. This means patients at home receive the same quality-controlled, pharmacist-verified products they would receive in a hospital — not medications assembled at the bedside or sourced from uncredentialed suppliers. → Contact Pharmko to learn more about our compounding services: 1-877-540-2003
Home Infusion Therapy in Florida
May 19, 2026
Pharmko provides home infusion therapy across Florida, IV antibiotics, IVIG, TPN, IDPN, and specialty medications. Licensed, accredited, and available 24/7 statewide.
Home Infusion Therapy in Texas
May 19, 2026
Pharmko provides home infusion therapy across Texas — IV antibiotics, IVIG, TPN, IDPN, and specialty medications. Licensed, accredited, and available 24/7 statewide.
 Phosphate Binders for Dialysis Patients
May 12, 2026
Learn how phosphate binders work for dialysis and CKD patients, the different types available, how they fit into a renal care plan, and how Pharmko supports dialysis centers with consistent supply.
 Home Infusion for Autoimmune Diseases
May 7, 2026
Learn how home infusion therapy supports autoimmune disease management,from IVIG for immune deficiencies to biologic infusions for inflammatory conditions. Pharmko serves 22+ states.
Subcutaneous vs IV Infusion: Which Delivery Route Is Right for Your Therapy
May 4, 2026
Learn the differences between subcutaneous and IV infusion delivery routes,how each works, which therapies use them, and how to choose the right option for your treatment.
Show More